Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
MWN-AI** Summary
Valneva SE, a specialty vaccine company, has announced that it will report its consolidated financial results for the full year 2025 on March 18, 2026. The report will be accompanied by a live webcast at 3 p.m. CET/10 a.m. EDT, where company executives will discuss the financial outcomes and provide insights into ongoing business developments. Investors and interested parties can access this webcast via Valneva's official website, with an archived version available post-event.
Valneva focuses on developing, manufacturing, and commercializing prophylactic vaccines aimed at addressing unmet medical needs. The company takes pride in its specialized approach, emphasizing expertise across various vaccine modalities aimed at delivering first-, best-, or only-in-class solutions. With a strong track record, Valneva has successfully advanced several vaccines through the R&D pipeline to regulatory approvals, currently marketing three proprietary travel vaccines. The revenues generated from its commercial operations support further advancements in its vaccine pipeline.
Among its key developments is a Lyme disease vaccine candidate, created in partnership with Pfizer, as well as the world's most advanced Shigella vaccine candidate. These are complemented by other vaccine candidates targeting global public health threats.
Valneva also provided a caution regarding forward-looking statements within the announcement, emphasizing that while certain expectations are based on current insights, they are subject to numerous risks and uncertainties that could materially affect future performance. The company intends to keep stakeholders informed but disclaims any obligation to update these forward-looking statements as circumstances evolve.
For further details, stakeholders can refer to Valneva's corporate website.
MWN-AI** Analysis
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) is poised to release its full year 2025 consolidated financial results on March 18, 2026. As a financial analyst, it is crucial to assess the company's strategic positioning ahead of this announcement, especially given its focus on specialty vaccines for unmet medical needs.
Valneva's prospects appear promising, particularly with its proprietary travel vaccines and cutting-edge candidates in clinical development, like the Lyme disease vaccine in partnership with Pfizer and the leading Shigella vaccine candidate. The company’s pipeline reflects its ability to innovate, indicating a potential for growth in revenues stemming from both existing products and new breakthroughs.
Investors should pay close attention to the upcoming earnings report for key indicators such as revenue performance, cost management, and updates on clinical trial milestones. The financial results will likely address how commercial revenues have evolved and how they support ongoing R&D investments. Given the company's reliance on these revenues to fund its growth, consistency and unexpected insights drawn from this discussion could signal emerging trends or challenges.
Moreover, Valneva operates in a sector characterized by unpredictability, including regulatory hurdles and competitive dynamics. As such, an analysis of any new regulatory developments, trial outcomes, and market competition should shape investor expectations leading into and following the results.
In terms of trading strategy, investors may consider positioning themselves based on speculative outcomes of the earnings report, while remaining cautious of the inherent risks highlighted in Valneva’s forward-looking statements. The next few weeks will be critical for gauging market sentiment, and prudent monitoring of broader market trends, as well as Valneva’s operational updates, will be essential for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lyon (France), March 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The Company will host a live webcast beginning at 3 p.m. CET/10 a.m. EDT to discuss the financial results and provide a business update.
The live webcast will be accessible on the Company’s website and made available as an archive after the event concludes. Please refer to this link: https://edge.media-server.com/mmc/p/qj2g7e52.
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.
Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelotfontaine@valneva.com | Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, to regulatory approval of product candidates and review of existing products, and financial guidance including projected product sales, total revenue and total R&D investments. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Attachment
FAQ**
How does Valneva SE INRLF plan to leverage its existing commercial vaccines to support the financial growth anticipated in their full year 2025 results, as announced for March 18, 2026?
Given the potential uncertainties highlighted, what strategies are in place for Valneva SE INRLF to mitigate risks associated with vaccine development and regulatory approvals?
Can Valneva SE INRLF provide insights on how the collaboration with Pfizer on the Lyme disease vaccine candidate has influenced its financial outlook for 2025?
What specific metrics should investors look for in the upcoming Valneva SE INRLF financial results webcast that may indicate progress in their vaccine pipeline and overall business performance?
**MWN-AI FAQ is based on asking OpenAI questions about Valneva SE (OTC: INRLF).
NASDAQ: INRLF
INRLF Trading
0.2% G/L:
$5.10 Last:
1,000 Volume:
$5.10 Open:
